Familial Mediterranean fever

Area of Science:

• Genetics
• Immunology
• Rheumatology

Background:

• Familial Mediterranean fever (FMF) is a prevalent hereditary autoinflammatory disease.
• Characterized by recurrent episodes of fever and serositis, FMF affects specific ethnic groups.
• Caused by mutations in the MEFV gene, encoding pyrin, which regulates inflammatory pathways.

Purpose of the Study:

• To summarize the key aspects of Familial Mediterranean Fever.
• To highlight the genetic basis, clinical manifestations, and complications of FMF.
• To discuss the established risk factors for amyloidosis and the efficacy of colchicine treatment.

Main Methods:

• Review of existing literature on Familial Mediterranean Fever.
• Analysis of genetic mutations (MEFV gene) and their role in pyrin function.
• Identification of risk factors for amyloidosis and evaluation of colchicine's therapeutic effects.

Main Results:

• FMF is an autosomal recessive disorder linked to MEFV gene mutations.
• Pyrin dysfunction leads to uncontrolled inflammation, with amyloidosis being a major complication.
• M694V homozygosity, male gender, and SAA1 genotype are risk factors for amyloidosis.

Conclusions:

• Colchicine is the primary treatment for FMF, achieving remission and reducing attack frequency.
• Colchicine therapy is crucial for preventing and halting the progression of renal amyloidosis.
• Understanding FMF genetics and risk factors aids in managing this inflammatory disease and its complications.